Lymphangioleiomyomatosis: New therapeutic approaches;Linfangioleiomiomatosis: Novedades terapeuticas

Archivos de Bronconeumologia

Volumn 47, Issue 12, 2011, Pages 579-580

  Casanova, álvaro ^a   Ancochea, Julio ^b  

^a Refractive Surgeon at Clínica Baviera Madrid   (Spain)

^b Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; LYMPHANGIOLEIOMYOMATOSIS; ADULT; ARTICLE; DRUG ANTAGONISM; EXPERIMENTAL THERAPY; FEMALE; GENETICS; HUMAN; LUNG TRANSPLANTATION; LUNG TUMOR; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; SPAIN; DIARRHEA; DISEASE ASSOCIATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HYPERCHOLESTEROLEMIA; INCIDENCE; LUNG FUNCTION; MOLECULAR BIOLOGY; MUCOSA INFLAMMATION; NAUSEA; OVARIECTOMY; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PREVALENCE; SIX MINUTE WALK TEST; SMOOTH MUSCLE CELL; SOMATIC MUTATION; TREATMENT DURATION; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; UNITED STATES; WORLD HEALTH ORGANIZATION;

AROMATASE INHIBITOR; DOXYCYCLINE; LETROZOLE; MATRIX METALLOPROTEINASE; NITRILE; RAPAMYCIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIAZOLE DERIVATIVE; GONADORELIN; HAMARTIN; MATRIX METALLOPROTEINASE INHIBITOR; PROGESTERONE; TAMOXIFEN; TUBERIN;

ADULT; AROMATASE INHIBITORS; CLINICAL TRIALS, PHASE II AS TOPIC; DOXYCYCLINE; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; LUNG NEOPLASMS; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; MATRIX METALLOPROTEINASES; MULTICENTER STUDIES AS TOPIC; NITRILES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; SIROLIMUS; SPAIN; THERAPIES, INVESTIGATIONAL; TRIAZOLES;

EID: 85047697436     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2011.06.016     Document Type: Article

References (19)

1. Johnson S.R. Lymphangioleiomyomatosis. Eur Respir J 2006, 27:1056-1065.
2. Von Stossel E. Uber muskulare Cirrhose der Lunge (Muscular cirrhosis of the lungs). Beitr Klin Tuberk 1937, 90:432-442.
3. Carsillo T., Astrinidis A., Henske E.P. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000, 97:6085-6090.
4. McCormack F.X., Inoue Y., Moss J., Singer L.G., Strange C., Nakata K., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011, 364:1595-1606.
5. Antón E., Casanova A., Xaubet A., Román A., Villena V., Montero M.C., et al. Lymphangioleiomyomatosis: a study of 72 patients from the Spanish registry. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26:85-91.
6. Kpodonu J., Massad M.G., Chaer R.A., Caines A., Evans A., Snow N.J., et al. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. J Heart Lung Transplant 2005, 24:1247-1253.
7. McCarty K.S., Mossler J.A., McLelland R., Sieker H.O. Pulmonary lymphangioleiomyomatosis responsive to progesterone. N Engl J Med 1980, 303:1461-1465.
8. Johnson S.R., Cordier J.F., Lazor R., Cottin V., Costabel U., Harari S., et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010, 35:14-26.
9. Ansótegui Barrera E., Mancheño Franch N., Vera-Sempere F., Padilla Alarcón J. Linfangioleiomiomatosis. Arch Bronconeumol 2011, 47:85-93.
10. Goncharova E.A., Goncharov D.A., Eszterhas A., Hunter D.S., Glassberg M.K., Yeung R.S., et al. Tuberin regulates p70 S6 activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 2002, 277:30958-30967.
11. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151.
12. Casanova A., Girón R.M., Acosta O., Barrón M., Valenzuela C., Ancochea J. Tratamiento de la linfangioleiomiomatosis con sirolimus. Arch Bronconeumol 2011, 47:470-472.
13. Matsui K., Takeda K., Yu Z.-X., Travis W.D., Moss J., Ferrans V.J. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioliomyomatosis. Arch Pathol Lab Med 2000, 124:267-275.
14. Bendeck M.P., Conte M., Zhang M., Nili N., Strauss B.H., Farwell S.M. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 2002, 160:1089-1095.
15. Moses M.A., Harper J., Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006, 354:2621-2622.
16. Glassberg M.K. Data presented at the LAM Foundation International Research Conference. Cincinnati, Ohio 2006.
17. Karbowniczek M., Astrinidis A., Balsara B.R., Testa J.R., Lium J.H., Colby T.V., et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003, 167:976-982.
18. Mokbel K. The evolving role of aromatase inhibitors in breast cancer. Int J Clin Oncol 2002, 7:279-283.
19. McCormack F.X. LAM Symposium, Cincinnati, EE. UU. Comunicación personal 2011.